The issue of immunology in stem cell therapies: A pharmaceutical perspective

Regenerative Medicine

Volumn 10, Issue 3, 2015, Pages 231-234

  Haworth, Richard ^a   Sharpe, Michaela ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

clinical trials; hESC; immune privilege; immune rejection; immunodeficient; iPS; MHC; mice; MSC; stem cells

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; MYCOPHENOLIC ACID; TACROLIMUS;

ALLOGENEIC STEM CELL TRANSPLANTATION; EDITORIAL; EMBRYONIC STEM CELL; GRAFT REJECTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE EVASION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LOW DRUG DOSE; MESENCHYMAL STEM CELL; MIXED LYMPHOCYTE REACTION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; ART; BIOLOGICAL THERAPY; IMMUNITY; STEM CELL;

CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNITY; PORTRAITS AS TOPIC; STEM CELLS;

EID: 84930011758     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.14.50     Document Type: Editorial

References (17)

1. Drukker M, Katz G, Urbach A et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc. Natl Acad. Sci. USA 99(15), 9864-9869 (2002).
2. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32(3), 252-260 (2014).
3. Jacobs SA, Roobrouck VD, Verfaillie CM, Van Gool SW. Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol. Cell Biol. 91(1), 32-39 (2013).
4. Pearl J.I, Wu J.C. The immunogenicity of ES cells and their differentiated progeny. In: The Immunological Barriers to Regenerative Medicine. Fairchild P.J. (Eds). Springer, New York, USA 37-48 (2013)
5. Fairchild P. Interview: Immunogenicity: the elephant in the room for regenerative medicine? Interviewed by Alexandra Hemsley. Regen. Med. 8(1), 23-26 (2013).
6. Fu X. The immunogenicity of cells derived from induced pluripotent stem cells. Cell Mol. Immunol. 11(1), 14-16 (2014).
7. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 474(7350), 212-215 (2011).
8. Goldring CE, Duffy PA, Benvenisty N et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell 8(6), 618-628 (2011).
9. Ito R, Takahashi T, Katano I, Ito M. Current advances in humanized mouse models. Cell Mol. Immunol. 9(3), 208-214 (2012).
10. Okamura RM, Lebkowski J, Au M, Priest CA, Denham J, Majumdar AS. Immunological properties of human embryonic stem cell-derived oligodendrocyte progenitor cells. J. Neuroimmunol. 192(1-2), 134-144 (2007).
11. Penn MS, Ellis S, Gandhi S et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ. Res. 110(2), 304-311 (2012).
12. von BL, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-Term engraftment and no ectopic tissue formation. Stem Cells 30(7), 1575-1578 (2012).
13. Schwartz SD, Hubschman JP, Heilwell G et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379(9817), 713-720 (2012).
14. Cell Therapy Catapult. https://ct.catapult.org.uk/-/cell-Therapy-catapult-roslin-cellsto-create-clinical-grade-stem-cells-To-Accelerate-researchinto-new-Treatments.
15. Cyranoski D. Stem-cell pioneer banks on future therapies. Nature 488(7410), 139 (2012).
16. Riolobos L, Hirata RK, Turtle CJ et al. HLA engineering of human pluripotent stem cells. Mol. Ther. 21(6), 1232-1241 (2013).
17. Pearl JI, Lee AS, Leveson-Gower DB et al. Short-Term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 8(3), 309-317 (2011).